氯吡格雷联合阿司匹林治疗急性冠状动脉综合征的效果及安全性  

Efficacy and safety of clopidogrel combined with aspirin on acute coronary syndrome

作　　者：胡雪梅 张宁[2] 王江敏 Hu Xuemei;Zhang Ning;Wang Jiangmin(Department of GeriatricsⅠ,North Hospital of Zhengzhou People’s Hospital,Zhengzhou 450000,China;Department of Hypertension,Zhengzhou People’s Hospital,Zhengzhou 450000,China)

机构地区：[1]郑州人民医院北院区老年医学一科,郑州450000 [2]郑州人民医院高血压科,郑州450000

出　　处：《中国实用医刊》2022年第16期90-93,共4页Chinese Journal of Practical Medicine

摘　　要：目的分析氯吡格雷联合阿司匹林在急性冠状动脉综合征(ACS)患者中的应用效果和安全性。方法抽取郑州人民医院2019年1月至2021年12月收治的65例ACS患者,按随机数字表法分为替格瑞洛组(32例)和氯吡格雷组(33例)。两组患者均给予常规治疗,在此基础上,替格瑞洛组予以替格瑞洛联合阿司匹林治疗,氯吡格雷组予以氯吡格雷联合阿司匹林治疗,两组均持续治疗6个月。记录两组患者治疗期间不良反应及不良心血管事件发生情况,比较两组治疗6个月后的临床效果;于治疗7 d、6个月时比较两组凝血功能指标。结果治疗6个月时,两组治疗总有效率比较差异未见统计学意义(P>0.05)。治疗6个月时,两组凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)短于治疗7 d,纤维蛋白原水平、血小板聚集率低于治疗7 d,差异均有统计学意义(P均<0.05);治疗6个月时,两组间PT、APTT、纤维蛋白原、血小板聚集率比较,差异未见统计学意义(P>0.05)。治疗期间,氯吡格雷组不良反应总发生率(6.25%,2/32)低于替格瑞洛组(27.27%,9/33),P<0.05;两组治疗期间不良心血管事件发生率比较差异未见统计学意义(P>0.05)。结论氯吡格雷、替格瑞洛分别联合阿司匹林治疗均可改善ACS患者凝血功能,降低不良心血管事件发生率,提高临床疗效,但氯吡格雷联合阿司匹林治疗可降低患者不良反应发生率,安全性高。Objective To analyze the effect and safety of clopidogrel combined with aspirin on patients with acute coronary syndrome(ACS).Methods Sixty-five patients with ACS treated in Zhengzhou People’s Hospital from January 2019 to December 2021 were selected and divided into ticagrelor group(32 cases)and clopidogrel group(33 cases)by random number table method.Both groups were given routine treatment,on this basis,patients in the ticagrelorol group were treated with ticagrelorol combined with aspirin,and patients in the clopidogrel group were treated with clopidogrel combined with aspirin.Both groups were treatment for 6 months.The adverse reactions and adverse cardiovascular events of the two groups during treatment were recorded,and the curative effects of the two groups after 6 months of treatment were compared.The coagulation function indexes of the two groups were compared 7 days and 6 months of treatment.Results After 6 months of treatment,there was no statistical significant difference in the total effective rate between the two groups(P>0.05);after 6 months of treatment,the prothrombin time(PT)and activated partial thromboplastin time(APTT)of both groups were shorter than those after 7 days of treatment,while the fibrinogen level and platelet aggregation rate were lower than those after 7 days of treatment,and the difference was statistically significant(all P<0.05).However,there was no statistical significant difference in PT,APTT,fibrinogen and platelet aggregation rate between the two groups 6 months of treatment(P>0.05).During the treatment period,the total incidence of adverse reactions in the clopidogrel group(6.25%,2/32)was lower than that in the ticagrelor group(27.27%,9/33),P<0.05;there was no statistical significant difference in the incidence of adverse cardiovascular events between the two groups during the treatment period(P>0.05).Conclusions Both clopidogrel and ticagrelor in combination with aspirin can improve coagulation function,reduce the incidence of adverse cardiovascular events and improve

关 键 词：急性冠状动脉综合征 氯吡格雷 阿司匹林 凝血功能 安全性 

分 类 号：R541.4[医药卫生—心血管疾病]